Johnson & Johnson (JNJ)vsVSee Health, Inc. (VSEE)
JNJ
Johnson & Johnson
$232.77
-2.08%
HEALTHCARE · Cap: $536.54B
VSEE
VSee Health, Inc.
$0.16
-3.64%
HEALTHCARE · Cap: $7.13M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 666447% more annual revenue ($96.36B vs $14.46M). JNJ leads profitability with a 21.8% profit margin vs -92.4%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
VSEE
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-71.4%
Fair Value
$135.80
Current Price
$232.77
$96.97 premium
Intrinsic value data unavailable for VSEE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -258.8% — below average capital efficiency
Revenue declined 4.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : VSEE
The strongest argument for VSEE centers on Debt/Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : VSEE
The primary concerns for VSEE are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while VSEE is a turnaround play — different risk/reward profiles.
VSEE carries more volatility with a beta of 0.42 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 28/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →VSee Health, Inc.
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
VSee Health, Inc. is a pioneering leader in the telehealth industry, delivering secure and intuitive video communication solutions specifically designed for healthcare professionals and patients. The company's versatile platform features essential functionalities, including remote patient monitoring, asynchronous messaging, and robust electronic medical record (EMR) interoperability, aimed at improving healthcare delivery efficiency and quality across diverse medical specialties. By prioritizing patient engagement and accessibility, VSee serves a broad international client base, strategically positioning itself to leverage the increasing demand for virtual care in the transforming healthcare landscape. With a focus on innovation and customer success, VSee Health is well-equipped for substantial growth as digital healthcare solutions become increasingly critical.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?